Product News

Alendronate Tablets

Marketed by:

Watson Pharmaceuticals Inc (Corona, CA)

Compared to:

Fosamax Tablets (Merck & Co Inc)

Indication:

February 6, 2008—Watson Pharmaceuticals announcedthat the company had initiated shipments of the authorizedgeneric of alendronate sodium in the 35- and70-mg once-weekly dosage strengths, after Fosamax'sloss of market exclusivity. Alendronate sodium is indicatedfor the treatment of osteoporosis in postmenopausalwomen and to increase bone mass in men withosteoporosis. Under the terms of a supply agreement,Merck will manufacture and supply the alendronatesodium tablets to Watson, which will market, sell, anddistribute the product in the United States.

Dosage Form:

Tablets: 35 and 70 mg

For More Information:

www.watson.com

Benzonatate Capsules

Marketed by:

ETHEX Corp (St. Louis, MO)

Compared to:

Tessalon Perles and soft gel capsules (Forest Laboratories)

Indication:

February 21, 2008—ETHEX Corp announced theapproval of Benzonatate Capsules, USP. Benzonatatecapsules are indicated for the symptomatic relief ofcough. Benzonatate acts peripherally by anesthetizingthe stretch receptors located in the respiratory passages,lungs, and pleura by dampening their activity andthereby reducing the cough reflex at its source. It beginsto act within 15 to 20 minutes, and its effect lasts for 3to 8 hours.

Dosage Form:

Capsules: 100 mg (in 100- and 500-ct bottles); 200 mg (in a 100-ct bottle); and a unit-dose product

For More Information:

800-321-1705

www.ethex.com

Calcipotriene Topical Solution 0.005%

Marketed by:

Fougera, a division of Nycomed US Inc (Melville, NY)

Compared to:

Dovonex (Warner-Chilcott)

Indication:

May 6, 2008—Fougera announcedthat it had received FDA approvalto bring to market the first generic Calcipotriene TopicalSolution 0.005% (scalp solution). Calcipotriene TopicalSolution is indicated for the topical treatment of chronic,moderately severe psoriasis of the scalp. In orderto administer it, the patient should comb the hair toremove scaly debris and, after suitably parting the hair,apply Calcipotriene Topical Solution 0.005% only to thelesions. Rub in gently and completely, taking care to preventthe solution from spreading to the forehead.

Dosage Form:

0.005% topical solution in a 60-mL bottle

For More Information:

800-645-9833

www.fougera.com

Nimodipine Capsules

Marketed by:

Heritage Pharmaceuticals Inc (Edison, NJ)

Compared to:

Nimotop (Bayer AG)

Indication:

June 15, 2008—Heritage Pharmaceuticals Inc haslaunched Nimodipine Capsules 30 mg. The product isindicated for the improvement of neurologic outcomeby reducing the incidence and severity of ischemicdeficits in patients with subarachnoidhemorrhage fromruptured intracranial berry aneurysms regardless of theirpostictus neurologic condition (ie, Hunt and Hess gradeI-V). This product is an AB-rated, soft-gel capsule and isavailable in 30- and 100-ct unit-dose blister cartons.

Dosage Form:

Capsules: 30 mg

For More Information:

866-901-1230

www.heritagepharma.com

Ropinirole Hydrochloride Tablets

Marketed by:

Roxane Laboratories Inc (Columbus, OH), a subsidiary of Boehringer Ingelheim Corp

Compared to:

Requip (GlaxoSmithKline)

Indication:

May 5, 2008—Roxane Laboratoriesannounced FDA approval of its abbreviatednew drug application for RopiniroleHydrochloride Tablets, 0.25, 0.5, 1, 2, 3,4, and 5 mg. The product is available inbottles of 100. Ropinirole Hydrochloride Tablets are indicatedfor the treatment of moderate-to-severe primaryrestless leg syndrome.

Dosage Form:

Tablets: 0.25, 0.5, 1, 2, 3, 4, and 5 mg

For More Information:

800-962-8364

www.roxane.com